Ángela de la Hoz Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ángela de la Hoz Rodríguez has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Marcello Di Martino
Department of Health Sciences, University of Piemonte Orientale, Novara, Italy; , Novara, Italy; Division of General Surgery, Azienda Ospedaliero Universitaria Maggiore della Carita, Novara, Italy, Italy
5 shared publications - Elena Martín-Pérez
Colorectal Surgery Department, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain
4 shared publications - Aurélien Dupré
Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
2 shared publications - Dimitri Dorcaratto
Colorectal Surgery Unit, Department of General and Digestive Surgery INCLIVA Biomedical Research Institute, Hospital Clínico Universitario de Valencia Valencia Spain
2 shared publications - Florian Primavesi
Department of General and Visceral Surgery, Ordensklinikum Linz - Barmherzige Schwestern, Linz, Austria
2 shared publications Georgina Ferret
Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain
2 shared publications
Latest Publications
- 18 July 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (11) , 6829-6842
Long-Term Outcomes of Perioperative Versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases: An International Multicentre Propensity-Score Matched Analysis with Stratification by Contemporary Risk-Scoring
There is still debate regarding the principal role and ideal timing of perioperative chemotherapy (CTx) for patients with upfront resectable colorectal liv
- 18 July 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (11) , 6829-6842
Long-Term Outcomes of Perioperative Versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases: An International Multicentre Propensity-Score Matched Analysis with Stratification by Contemporary Risk-Scoring
There is still debate regarding the principal role and ideal timing of perioperative chemotherapy (CTx) for patients with upfront resectable colorectal liv
- 9 July 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (11) , 1-2
ASO Visual Abstract: Long-Term Outcomes of Perioperative versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases—An International Multicenter Propensity-Score Matched Analysis with Stratification by Contemporary Risk Scoring
- 9 July 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (11) , 1-2
ASO Visual Abstract: Long-Term Outcomes of Perioperative versus Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases—An International Multicenter Propensity-Score Matched Analysis with Stratification by Contemporary Risk Scoring
- 30 April 2021
- Published by Elsevier in Cirugía Española (English Edition)
- Vol. 99 (5) , 383
Hepatic granuloma mimicking an intrahepatic cholangiocarcinoma: An unusual presentation
- 30 April 2021
- Published by Elsevier in Cirugía Española (English Edition)
- Vol. 99 (5) , 383
Hepatic granuloma mimicking an intrahepatic cholangiocarcinoma: An unusual presentation
- 19 March 2021
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 47 (3) , 683-692
Multicentre cohort study of acute cholecystitis management during the COVID-19 pandemic
Purpose To analyse acute cholecystitis (AC) management during the first pandemic outbreak after the recommendations given by the surgical societies estimating: morbidity, length of hospital stay, mortality and hospital-acquired SARS-CoV-2 infection rate. Methods Multicentre-combined (retrospective–prospective) cohort study with AC patients in the Community of Madrid between 1st March and 30th May 2020. 257 AC patients were involved in 16 public hospital. Multivariant binomial logistic regression (MBLR) was applied to mortality. Results Of COVID-19 patients, 30 were diagnosed at admission and 12 patients were diagnosed during de admission or 30 days after discharge. In non-COVID-19 patients, antibiotic therapy was received in 61.3% of grade I AC and 40.6% of grade II AC. 52.4% of grade III AC were treated with percutaneous drainage (PD). Median hospital stay was 5 [3–8] days, which was higher in the non-surgical treatment group with 7.51 days (p < 0.001) and a 3.25% of mortality rate (p < 0.21). 93.3% of patients with SARS-CoV-2 infection at admission were treated with non-surgical treatment (p = 0.03), median hospital stay was 11.0 [7.5–27.5] days (p < 0.001) with a 7.5% of mortality rate (p > 0.05). In patients with hospital-acquired SARS-CoV-2 infection, 91.7% of grade I–II AC were treated with non-surgical treatment (p = 0.037), with a median hospital stay of 16 [4–21] days and a 18.2% mortality rate (p > 0.05). Hospital-acquired infection risk when hospital stay is > 7 days is OR 4.7, CI 95% (1.3–16.6), p = 0.009. COVID-19 mortality rate was 11.9%, AC severity adjusted OR 5.64 (CI 95% 1.417–22.64). In MBLR analysis, age (OR 1.15, CI 95% 1.02–1.31), SARS-CoV-2 infection (OR 14.49, CI 95% 1.33–157.81), conservative treatment failure (OR 8.2, CI 95% 1.34–50.49) and AC severity were associated with an increased odd of mortality. Conclusion In our population, during COVID-19 pandemic, there was an increase of non-surgical treatment which was accompanied by an increase of conservative treatment failure, morbidity and hospital stay length which may have led to an increased risk hospital-acquired SARS-CoV-2 infection. Age, SARS-CoV-2 infection, AC severity and conservative treatment failure were mortality risk factors.
- 19 March 2021
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 47 (3) , 683-692
Multicentre cohort study of acute cholecystitis management during the COVID-19 pandemic
Purpose To analyse acute cholecystitis (AC) management during the first pandemic outbreak after the recommendations given by the surgical societies estimating: morbidity, length of hospital stay, mortality and hospital-acquired SARS-CoV-2 infection rate. Methods Multicentre-combined (retrospective–prospective) cohort study with AC patients in the Community of Madrid between 1st March and 30th May 2020. 257 AC patients were involved in 16 public hospital. Multivariant binomial logistic regression (MBLR) was applied to mortality. Results Of COVID-19 patients, 30 were diagnosed at admission and 12 patients were diagnosed during de admission or 30 days after discharge. In non-COVID-19 patients, antibiotic therapy was received in 61.3% of grade I AC and 40.6% of grade II AC. 52.4% of grade III AC were treated with percutaneous drainage (PD). Median hospital stay was 5 [3–8] days, which was higher in the non-surgical treatment group with 7.51 days (p < 0.001) and a 3.25% of mortality rate (p < 0.21). 93.3% of patients with SARS-CoV-2 infection at admission were treated with non-surgical treatment (p = 0.03), median hospital stay was 11.0 [7.5–27.5] days (p < 0.001) with a 7.5% of mortality rate (p > 0.05). In patients with hospital-acquired SARS-CoV-2 infection, 91.7% of grade I–II AC were treated with non-surgical treatment (p = 0.037), with a median hospital stay of 16 [4–21] days and a 18.2% mortality rate (p > 0.05). Hospital-acquired infection risk when hospital stay is > 7 days is OR 4.7, CI 95% (1.3–16.6), p = 0.009. COVID-19 mortality rate was 11.9%, AC severity adjusted OR 5.64 (CI 95% 1.417–22.64). In MBLR analysis, age (OR 1.15, CI 95% 1.02–1.31), SARS-CoV-2 infection (OR 14.49, CI 95% 1.33–157.81), conservative treatment failure (OR 8.2, CI 95% 1.34–50.49) and AC severity were associated with an increased odd of mortality. Conclusion In our population, during COVID-19 pandemic, there was an increase of non-surgical treatment which was accompanied by an increase of conservative treatment failure, morbidity and hospital stay length which may have led to an increased risk hospital-acquired SARS-CoV-2 infection. Age, SARS-CoV-2 infection, AC severity and conservative treatment failure were mortality risk factors.
- Open Access
- 1 January 2021
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 11, e2021245
Solitary fibrous tumor of the pancreas
Autops Case Rep, vol.11, e2021245, 2021
- 1 January 2021
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 11, e2021245
Open AccessSolitary fibrous tumor of the pancreas
Autops Case Rep, vol.11, e2021245, 2021
- 1 January 2017
- Published by Elsevier in Cirugía Española
- Vol. 95 (1) , 45
Hematoma subcapsular esplénico secundario a metástasis de carcinoma epidermoide anal
- 1 January 2017
- Published by Elsevier in Cirugía Española
- Vol. 95 (1) , 45
Hematoma subcapsular esplénico secundario a metástasis de carcinoma epidermoide anal